QNCX
Quince Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$31.32
+2.52%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 36.0K | 142.0K | — | — | — |
| Gross Profit | (36.0K) | (142.0K) | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 33.0M | 35.4M | 18.6M | 9.4M | 25.2M |
| SG&A Expense | 27.8M | 15.0M | 17.6M | 17.7M | 26.0M |
| General & Admin Expense | 27.8M | 15.0M | 17.6M | 17.7M | 26.0M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 62.8M | (142.0K) | 21.1M | 7.5M | 825.0K |
| Total Operating Expenses | 123.6M | 50.3M | 57.3M | 34.6M | 52.0M |
| Cost and Expenses | 123.7M | 50.4M | 57.3M | 34.6M | 52.0M |
| Operating Income (EBIT) | (123.7M) | (50.4M) | (57.3M) | (34.6M) | (52.0M) |
| Non-Operating | |||||
| Interest Income | 1.3M | 1.2M | 2.9M | 3.5M | 1.1M |
| Interest Expense | — | — | — | — | 568.0K |
| Net Interest Income | 1.3M | 1.2M | 2.9M | 3.5M | 500.0K |
| Other Non-Op Income/Expense | 29.0M | (30.3M) | 544.0K | 3.0M | 71.0K |
| Non-Operating Income (excl Interest) | (51.2M) | 30.3M | (21.1M) | (7.5M) | (825.0K) |
| EBT (Pre-Tax Income) | (94.6M) | (80.8M) | (56.7M) | (31.6M) | (51.9M) |
| Income Tax Expense | (2.2M) | 3.2M | 87.0K | (197.0K) | (284.0K) |
| Bottom Line | |||||
| Net Income | (92.5M) | (84.0M) | (56.8M) | (31.4M) | (51.7M) |
| Earnings from Cont. Ops | (92.5M) | (84.0M) | (56.8M) | (31.4M) | (51.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (92.5M) | (84.0M) | (56.8M) | (31.4M) | (51.7M) |
| Per Share | |||||
| Basic EPS | ($68.91) | ($336.00) | ($262.00) | ($168.00) | ($308.00) |
| Diluted EPS | ($68.91) | ($336.00) | ($262.00) | ($168.00) | ($308.00) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 6.1M | 250485 | 216311 | 186186 | 167483 |
| Diluted Shares Outstanding | 6.1M | 250485 | 216311 | 186186 | 167483 |
| Profitability Metrics | |||||
| EBITDA | (72.3M) | (80.6M) | (36.0M) | (26.8M) | (51.0M) |
| D&A | 111.0K | 142.0K | 186.0K | 322.0K | 204.0K |
| EBIT | (72.4M) | (80.8M) | (36.2M) | (27.1M) | (51.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026